Effect of reboxetine on depression in Parkinson's disease patients.
- 15 April 2002
- journal article
- clinical trial
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 63 (4) , 300-304
- https://doi.org/10.4088/jcp.v63n0405
Abstract
Depression occurs frequently in patients with Parkinson's disease and appears to be associated with increased disability and reduced quality of life. Pharmacologic treatment with tricyclic antidepressants or serotonin reuptake inhibitors may produce adverse effects on cognition or motor functions in Parkinson's disease patients. The efficacy of reboxetine, a novel norepinephrine reuptake inhibitor, has been shown in major depressive disorder, with specific effects on motivation and negligible effects on psychomotor and cognitive function.Keywords
This publication has 0 references indexed in Scilit: